Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder

Otsuka

Status: Completed

Conditions: Schizophrenia; Bipolar Disorder

Treatments: Drug: Aripiprazole

Study type: Observational

Funder types: Industry

Identifiers

NCT00216723

Korea Abilify PMS

Details and patient eligibility

About

This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.

Full description

This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.

Qualified schizophrenia patients will be enrolled to an 12-week treatment phase of Aripiprazole by physician's assessment.

Qualified bipolar disorder patients will be enrolled to an 8-week treatment phase of Aripiprazole by physician's assessment.

This study will be continued for 6 years. The final report of Aripiprazole PMS will be submitted to KFDA on December 28, 2009.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with a schizophrenia or schizoaffective disorder or bipolar disorder according to DSM-IV criteria
• Age: more than 18 years of age

Exclusion criteria

• Unqualified patients judged by study investigator(s)